HTF Market Intelligence released a new research report of 46 pages on title 'Sosei Group Corp (4565) - Pharmaceuticals & Healthcare - Deals and Alliances Profile' with detailed analysis, forecast and strategies.

Summary

Sosei Group Corp (Sosei) is a biopharmaceutical company that develops and commercializes drugs. The company’s products include NorLevo, NVA237, QVA149 and SO-1105. Its NorLevo product is an oral emergency contraceptive and SO-1105 is an antifungal agent, administered as a muco-adhesive buccal tablet for the treatment of oropharyngeal candidiasis in immunocompromised patients. Sosei’s NVA237 is a long acting bronchodilator for the treatment of chronic obstructive pulmonary disease. The company provides treatment of Alzheimer's disease, schizophrenia, cancer, migraine, addiction, metabolic disease, and other indications. It operates through various pharmaceutical companies. The company has presence in Japan, Europe and North American pharmaceutical markets. Sosei is headquartered in Tokyo, Japan.

Make an enquiry before buying this Report @ https://www.htfmarketreport.com/enquiry-before-buy/254144-sosei-group-corp-2

Sosei Group Corp (4565) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

The derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

View Detailed Table of Content @ https://www.htfmarketreport.com/reports/254144-sosei-group-corp-2


Table of Contents

List of Tables 4
List of Figures 5
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Sosei Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Sosei Group Corp, Medical Devices Deals, 2011 to YTD 2017 10
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Sosei Group Corp, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Heptares Therapeutics Raises US$21 Million In Series B Financing 13
Partnerships 14
Heptares Therapeutics Enters into Research Agreement with University of Cambridge 14
Pluristem Therapeutics to Partner with Sosei Corporate Venture Capital 15
Jitsubo Enters into Agreement with Heptares Therapeutics 15
Heptares Therapeutics and leadXpro Enter into Agreement 16
Heptares Therapeutics to Form Partnership with Kymab 17
Heptares Therapeutics Enters into Agreement with Pfizer 18
Sosei Plans to Enter into Agreement with Novartis 19
Sosei Enters Into Distribution Agreement With Fujifilm Pharma For SO-1105 19
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 20

…….Continued

Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=254144

Contact Us:
CRAIG FRANCIS (PR & Marketing Manager)
[email protected]
Ph: +1 (206) 317 1218